signal regulatory protein alpha pseudogene 1Genealiases: PTPNS1L · SIRPA2P
Q-omics provides the consensus-scored SIRPAP1 profile across patient tissues and cancer cell-line models. SIRPAP1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SIRPAP1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SIRPAP1 RNA expression shows 16,211 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where SIRPAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SIRPAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SIRPAP1 survival associations across molecular data types. SIRPAP1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SIRPAP1 RNA expression–survival associations across cancer types. High SIRPAP1 expression shows unfavorable associations in LUSC, KIRP and THYM, but favorable associations in KIRC, CESC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SIRPAP1 RNA expression.
This table summarizes SIRPAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SIRPAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SIRPAP1 shows lower tumor expression in KICH, LUAD, BRCA and LUSC and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher SIRPAP1 RNA expression in tumor versus normal tissue (log2 FC = +0.630, t-test p < 0.001).
This table shows molecular features associated with SIRPAP1 in patient tissues and cancer cell lines. In patient samples, SIRPAP1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
